ACAT1

Across TCGA pan-cancer cohorts, ACAT1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ACAT1 data layer compared with 20 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ACAT1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ACAT1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and COAD are the cancer types where ACAT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	III,IV	1.000	0.641	.002	39	view →
LUAD	OS	Tertile	All	0.962	0.773	.019	7	view →
COAD	DFS	Median	II,III,IV	1.000	0.887	.030	6	view →
UCEC	OS	Median	All	0.860	0.967	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ACAT1–PDAC (OS)

Open the PDAC breakdown →